Archive

Filter

Sell to close the February 17, 2017 call on PayPal Holdings (PYPL) with a strike price of $41.00 at $.62 or higher. Symbol (PYPL170217C41) There is still some value left in these calls that expire tomorrow. Although I am booking a loss, the calls are in the money and holders should… Read More

There are several key conference calls I’ll be listening to this week, but the two below are the most important to the Profit Catalyst Alert portfolio. Although we just sold Patrick industries, its commentary will influence how Winnebago, where we have a put position, trades. Please note you will need to… Read More

Carbonite: The company beat fourth quarter earnings by 2 cents and slightly raised 2017 estimates. The stock is weak because it lowered first quarter estimates, which pushes earnings out to quarters two through four. Its purchase of Double Take closed a bit later than expected which pushed revenue out. In… Read More

Sell Patrick Industries (NSDQ: PATK) for a 41% gain. It’s been a fabulous ride with Patrick Industries, which is up 41% in less than five months since my recommendation. Competitor LCI Industries reported a strong quarter last week but the stock sagged 4% – an indication that investor hopes are… Read More

Sell to close the April 21, 2017 call on The Chemours Company (CC) with a strike price of $29.00 at $4.49 or higher (Symbol (CC170421C29)) for a 140% gain in three short trading days. Chemours bulls got a nice boost today due to a litigation settlement announced this morning. I still… Read More

I recommended The Chemours Company stock (NYSE: CC) earlier today. For those subscribers who prefer option trades, I recommend the following: Buy to open the April 21, 2017 call on The Chemours Company (CC) with a strike price of $29.00 at $1.85 or lower. Symbol (CC170421C29)… Read More

  The Chemours Company (NYSE: CC)  is one of two publicly traded companies able to cash in on on a major worldwide regulatory change regarding chemicals used as refrigerants. Chemours’ Opteon is one of two acceptable substitutes for current refrigerants. Target: $48 Buy Up To: $30 The Kigali agreement, signed in November… Read More

Buy Jazz Pharmaceuticals (NSDQ: JAZZ) up to $130 per share.    Jazz Pharma  is both  profitable and fast growing – an unusual combination in its industry. Its recent acquisition of Celator Pharmaceuticals last fall gives it a new drug candidate for Acute Myeloid Leukemia (AML). In the meantime, the company… Read More